Evaluation of the Quality of Adjuvant Endocrine Therapy Delivery for Breast Cancer Care in the United States
暂无分享,去创建一个
O. Olopade | D. Winchester | D. Huo | K. Yao | N. Hou | Bobby Daly
[1] Hhs Centers for Medicare Medicaid Services,et al. Medicare Program; Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentive Under the Physician Fee Schedule, and Criteria for Physician-Focused Payment Models. Final rule with comment period. , 2016, Federal register.
[2] Purushottam W. Laud,et al. Medicare D Subsidies and Racial Disparities in Persistence and Adherence With Hormonal Therapy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] A. Giobbie-Hurder,et al. Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Griggs,et al. Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] M. Howell,et al. No Exit: Identifying Avoidable Terminal Oncology Intensive Care Unit Hospitalizations. , 2016, Journal of oncology practice.
[6] M. Martini,et al. National Evaluation of Hospital Performance on the New Commission on Cancer Melanoma Quality Measures , 2016, Annals of Surgical Oncology.
[7] R. Conti,et al. A Pathway Through the Bundle Jungle. , 2016, Journal of oncology practice.
[8] Xianglin L. Du,et al. Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D , 2016, Medical Oncology.
[9] J. Forbes,et al. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.
[10] A. Partridge,et al. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer. , 2015, Journal of the National Cancer Institute.
[11] S. Tucker,et al. Impact of Fertility Concerns on Tamoxifen Initiation and Persistence. , 2015, Journal of the National Cancer Institute.
[12] M. Rendi,et al. Adjuvant Endocrine Therapy in Patients with Ductal Carcinoma In Situ: A Population-Based Retrospective Analysis from 2005 to 2012 in the National Cancer Data Base , 2015, Annals of Surgical Oncology.
[13] O. Olopade,et al. A perfect storm: How tumor biology, genomics, and health care delivery patterns collide to create a racial survival disparity in breast cancer and proposed interventions for change , 2015, CA: a cancer journal for clinicians.
[14] Sallie J. Weaver,et al. Reviewing cancer care team effectiveness. , 2015, Journal of oncology practice.
[15] F. Montemurro,et al. Adjuvant ovarian suppression in premenopausal breast cancer. , 2015, The New England journal of medicine.
[16] Xianglin L. Du,et al. Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage , 2015, Medical Oncology.
[17] R. Greil,et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] O. Olopade,et al. Race, ethnicity, and the diagnosis of breast cancer. , 2015, Journal of the American Medical Association (JAMA).
[19] S. Martino,et al. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] S. Gomez,et al. Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. , 2014, JAMA.
[21] A. Giobbie-Hurder,et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. , 2014, The New England journal of medicine.
[22] K. Bilimoria,et al. Comparing national cancer registries: The National Cancer Data Base (NCDB) and the surveillance, epidemiology, and end results (SEER) program , 2014, Journal of surgical oncology.
[23] S. Wheeler,et al. Racial disparities in initiation of adjuvant endocrine therapy of early breast cancer , 2014, Breast Cancer Research and Treatment.
[24] E. Mort,et al. A decade after to Err is Human: what should health care leaders be doing? , 2014, Physician executive.
[25] M. Hurlbert,et al. Increasing Black:White disparities in breast cancer mortality in the 50 largest cities in the United States. , 2014, Cancer epidemiology.
[26] B. Esterni,et al. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] L. Kachnic,et al. Challenges in the delivery of quality breast cancer care: initiation of adjuvant hormone therapy at an urban safety net hospital. , 2014, Journal of oncology practice.
[28] R. Chlebowski,et al. Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings , 2014, Cancer Prevention Research.
[29] A. Kuten,et al. Should radiotherapy be omitted in women age 70 years or older with early breast cancer? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Barbara L. Smith,et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] N. Bickell,et al. Breast Cancer Treatment Decision-Making: Are We Asking Too Much of Patients? , 2013, Journal of General Internal Medicine.
[32] J. Griggs,et al. Adjuvant endocrine therapy initiation and persistence in a diverse sample of patients with breast cancer , 2013, Breast Cancer Research and Treatment.
[33] F. Boscoe,et al. Initiation of adjuvant hormone therapy by Medicaid insured women with nonmetastatic breast cancer. , 2012, Journal of the National Cancer Institute.
[34] M. Cobleigh,et al. Adjuvant endocrine therapy for breast cancer. , 2012, Oncology.
[35] Sally W. Vernon,et al. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review , 2012, Breast Cancer Research and Treatment.
[36] H. Wasvary,et al. Multidisciplinary management of colorectal cancer enhances access to multimodal therapy and compliance with National Comprehensive Cancer Network (NCCN) guidelines , 2012, International Journal of Colorectal Disease.
[37] David S Morrison,et al. Effects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 women , 2012, BMJ : British Medical Journal.
[38] A. Neugut,et al. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL) , 2012, Breast Cancer Research and Treatment.
[39] J. Warren,et al. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D. , 2011, Medicare & medicaid research review.
[40] R Peto,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[41] Dawn L. Hershman,et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.
[42] Dawn L Hershman,et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[44] A. Stewart,et al. Trends in Contralateral Prophylactic Mastectomy for Unilateral Cancer: A Report From the National Cancer Data Base, 1998–2007 , 2010, Annals of Surgical Oncology.
[45] C. Ko,et al. Comparison of commission on cancer-approved and -nonapproved hospitals in the United States: implications for studies that use the National Cancer Data Base. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] F. Camacho,et al. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] A. Jemal,et al. Temporal trends in breast cancer mortality by state and race , 2008, Cancer Causes & Control.
[48] C. Ko,et al. The National Cancer Data Base: A Powerful Initiative to Improve Cancer Care in the United States , 2008, Annals of Surgical Oncology.
[49] E. Feuer,et al. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999. , 2006, Journal of the National Cancer Institute. Monographs.
[50] G. Hortobagyi,et al. Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a,bN0M0): a review of the literature. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. Gradishar. Landmark trials in endocrine adjuvant therapy for breast carcinoma , 2006, Cancer.
[52] A. Goldhirsch,et al. Minimal and small size invasive breast cancer with no axillary lymph node involvement: the need for tailored adjuvant therapies. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] E. Feuer,et al. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975-1999. , 2002, Journal of the National Cancer Institute.
[54] Robert J. Mayer,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[55] Y. Morishita,et al. [Adjuvant endocrine therapy for breast cancer]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.
[56] R. Deyo,et al. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.
[57] A. Shimada,et al. Adjuvant Hormone Therapy for Breast Cancer , 2019, Breast Diseases.
[58] A. Jemal,et al. Breast cancer statistics, 2015: Convergence of incidence rates between black and white women , 2016, CA: a cancer journal for clinicians.
[59] B. Hickey,et al. Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. , 2013, American journal of otolaryngology.
[60] Andrew Ma,et al. Comparison of Cases Captured in the National Cancer Data Base with Those in Population-based Central Cancer Registries , 2013, Annals of Surgical Oncology.
[61] M Markman,et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.
[62] K C Cain,et al. Analysis of survival by tumor response. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.